Mass spectrometry quantifies target engagement for a KRASG12C inhibitor in FFPE tumor tissue

被引：0
|
作者：
Andrew G. Chambers
David C. Chain
Steve M. Sweet
Zifeng Song
Philip L. Martin
Matthew J. Ellis
Claire Rooney
Yeoun Jin Kim
机构：
[1] AstraZeneca,Early Oncology
[2] AstraZeneca,Early Oncology
来源：
Clinical Proteomics | 2023年 / 20卷
关键词：
Mass spectrometry; Targeted proteomics; FFPE; Translational medicine; Target engagement;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] A next-generation KRASG12C inhibitor ABSK071 demonstrated broad synergy with other therapeutic agents in KRASG12C mutated cancer models
    Ying, Haiyan
    Guo, Fushen
    Peng, Juan
    Wang, Jie
    Zhang, Jie
    Liu, Manqi
    Zhu, Zhixuan
    Chen, Zhui
    CANCER RESEARCH, 2023, 83 (08)
  • [22] Sotorasib: a KRASG12C inhibitor for non-small cell lung cancer
    Ganguly, Arghya
    Yoo, Euna
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2022, 43 (06) : 536 - 537
  • [23] Expanding the KRASG12C Inhibitor Class: What Do We Need Next?
    Norman, Aurora
    Adjei, Alex A.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (07) : 844 - 846
  • [24] In silico drug design using KRASG12C as a theranostic target for pancreatic cancer
    Barbosa, Barbara M.
    Martins, Allana C. F.
    Gomes, Roberto S.
    Rainho, Claudia A.
    CANCER RESEARCH, 2022, 82 (22) : 84 - 84
  • [25] Discovery of AZD4625, a Covalent Allosteric Inhibitor of the MutantGTPase KRASG12C
    Kettle, Jason G.
    Bagal, Sharan K.
    Bickerton, Sue
    Bodnarchuk, Michael S.
    Boyd, Scott
    Breed, Jason
    Carbajo, Rodrigo J.
    Cassar, Doyle J.
    Chakraborty, Atanu
    Cosulich, Sabina
    Cumming, Iain
    Davies, Michael
    Davies, Nichola L.
    Eatherton, Andrew
    Evans, Laura
    Feron, Lyman
    Fillery, Shaun
    Gleave, Emma S.
    Goldberg, Frederick W.
    Hanson, Lyndsey
    Harlfinger, Stephanie
    Howard, Martin
    Howells, Rachel
    Jackson, Anne
    Kemmitt, Paul
    Lamont, Gillian
    Lamont, Scott
    Lewis, Hilary J.
    Liu, Libin
    Niedbala, Michael J.
    Phillips, Christopher
    Polanski, Radek
    Raubo, Piotr
    Robb, Graeme
    Robinson, David M.
    Ross, Sarah
    Sanders, Matthew G.
    Tonge, Michael
    Whiteley, Rebecca
    Wilkinson, Stephen
    Yang, Junsheng
    Zhang, Wenman
    JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (09) : 6940 - 6952
  • [26] Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors
    Lanman, Brian A.
    Allen, Jennifer R.
    Allen, John G.
    Amegadzie, Albert K.
    Ashton, Kate S.
    Booker, Shon K.
    Chen, Jian Jeffrey
    Chen, Ning
    Frohn, Michael J.
    Goodman, Guy
    Kopecky, David J.
    Liu, Longbin
    Lopez, Patricia
    Low, Jonathan D.
    Ma, Vu
    Minatti, Ana E.
    Nguyen, Thomas T.
    Nishimura, Nobuko
    Pickrell, Alexander J.
    Reed, Anthony B.
    Shin, Youngsook
    Siegmund, Aaron C.
    Tamayo, Nuria A.
    Tegley, Christopher M.
    Walton, Mary C.
    Wang, Hui-Ling
    Wurz, Ryan P.
    Xue, May
    Yang, Kevin C.
    Achanta, Pragathi
    Bartberger, Michael D.
    Canon, Jude
    Hollis, L. Steven
    McCarter, John D.
    Mohr, Christopher
    Rex, Karen
    Saiki, Anne Y.
    San Miguel, Tisha
    Volak, Laurie P.
    Wang, Kevin H.
    Whittington, Douglas A.
    Zech, Stephan G.
    Lipford, J. Russell
    Cee, Victor J.
    JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (01) : 52 - 65
  • [27] The small molecule KRAS inhibitor, TEB-17231, blocks tumor progression and overcomes KRASG12C inhibitor mediated resistance
    Xu, Zusheng
    Weaver, David T.
    Drakas, Robert
    Lou, Yangtong
    CANCER RESEARCH, 2023, 83 (07)
  • [28] KRAS mutant gene editing prevents tumor growth in vivo and overcomes acquired resistance to KRASG12C inhibitor
    Divita, Gilles
    Guzman-Gonzales, Veronica
    Grunenberger, Audrey
    Czuba, Elodie
    Guidetti, Melanie
    Josserand, Veronique
    Desai, Neil
    CANCER RESEARCH, 2023, 83 (07)
  • [29] The clinical dual KRASG12C inhibitor FMC-376 has demonstrated potential as both a monotherapy and in combination for the treatment of patients with KRASG12C mutation positive NSCLC
    Wang, Yan
    Roberts, Allison
    Calses, Philamer
    Neve, Richard M.
    Staunton, Jocelyn
    Webster, Kevin R.
    CANCER RESEARCH, 2024, 84 (06)
  • [30] Accelerating the Validation of Endogenous On-Target Engagement and In Cellulo Kinetic Assessment for Covalent Inhibitors of KRASG12C in Early Drug Discovery
    Kantae, Vasudev
    Polanski, Radoslaw
    Lewis, Hilary J.
    Haider, Afreen
    Barratt, Derek
    Srinivasan, Bharath
    ACS CHEMICAL BIOLOGY, 2022, 17 (08) : 2366 - 2376
12345